Comparison of orlistat treatment and placebo in obese type 2 diabetic patients

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 12, 2010, Pages 1971-1982

  Derosa, Giuseppe ^a   Maffioli, Pamela ^a   Salvadeo, Sibilla A T ^a   Ferrari, Ilaria ^a   Gravina, Alessia ^a   Mereu, Roberto ^a   D'Angelo, Angela ^a   Fogari, Elena ^a   Palumbo, Ilaria ^a   Randazzo, Sabrina ^a   Cicero, Arrigo F G ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Inflammatory parameters; Orlistat; TNF ; Type 2 diabetes; Vaspin

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GLUCOSE; INSULIN; LEPTIN; LIPID; PLACEBO; SERINE PROTEINASE INHIBITOR; TETRAHYDROLIPSTATIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASPIN; ADIPOQ PROTEIN, HUMAN; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; AUTACOID; GLUCOSE BLOOD LEVEL; LACTONE; SERPINA12 PROTEIN, HUMAN;

ABDOMINAL PAIN; ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION DISORDER; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; FECES INCONTINENCE; FEMALE; FLATULENCE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; WAIST CIRCUMFERENCE; BLOOD; DIABETES MELLITUS, TYPE 2; IMMUNOLOGY; ITALY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PLACEBO EFFECT; TIME; TREATMENT OUTCOME;

ADIPONECTIN; ANTI-OBESITY AGENTS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION MEDIATORS; INSULIN; INSULIN RESISTANCE; ITALY; LACTONES; LEPTIN; LIPIDS; MALE; MIDDLE AGED; OBESITY; PLACEBO EFFECT; SERPINS; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; WAIST CIRCUMFERENCE;

EID: 77954801789     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.493557     Document Type: Article

References (61)

1. Kumanyika S, Jeffery RW, Morabia A, et al. Obesity prevention: the case for action. Int J Obes Relat Metab Disord 2002;26:425-436
2. Keller U. From obesity to diabetes. Int J Vitam Nutr Res 2006;76:172-177
3. American Diabetes Association. Nutrition principles and recommendations in diabetes. Diabetes Care 2004;27(Suppl 1):36-46
4. Lee M, Aronne LJ. Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction. Am J Cardiol 2007;99:68B-79B
5. Leung WY, Thomas GN, Chan JC, Tomlinson B. Weight management and current options in pharmacotherapy: orlistat and sibutramine. Clin Ther 2003;25:58-80
6. Zhi J, Melia AT, Guerciolini R, et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994;56:82-85
7. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-161 (Pubitemid 38196725)
8. Henness S, Perry CM. Orlistat: a review of its use in the management of obesity. Drugs 2006;66:1625-1656
9. Curran MP, Scott LJ. Orlistat: a review of its use in the management of patients with obesity. Drugs 2004;64:2845-64 Filippatos TD, Derdemezis CS, Gazi IF, et al. Orlistat-associated adverse effects and drug interactions. A critical review. Drug Saf 2008;31:53-65
10. McDuffie JR, Calis KA, Uwaifo GI, et al. Efficacy of orlistat as an adjunct to behavioural treatment in overweight African American and Caucasian adolescents with obesity-related co-morbid conditions. J Pediatr Endocrinol Metab 2004;17:307-319
11. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88-136
12. World Health Organization. Obesity: preventing and managing the global epidemic. Report of WHO consultation on obesity. Geneva: WHO; 1997
13. Lichtenstein AH, Appel LJ, Brands M, et al. Summary of American Heart Association diet and lifestyle recommendations revision 2006. Arterioscler Thromb Vasc Biol 2006;26:2186-2191
14. Borg G. Perceived exertion as an indicator of somatic stress. Scand J Rehabil Med 1970;2:92-98
15. Misra A, Garg A. Leptin: its receptor and obesity. J Invest Med 1996;44:540-548
16. Zhang M, Tracey K. The cytokine handbook. 3rd edition. Academic Press, San Diego; 1988
17. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941-946
18. Hida K, Wada J, Eguchi J, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA 2005;102:10610-5
19. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999;45:2136-2141
20. Bunn HF, Gabbay KH, Gallop PM. The glycosylation of haemoglobin. Relevance to diabetes mellitus. Science 1978;200:21-27
21. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999;16:716-730
22. Heding LG. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 1972; 8. 260-266.
23. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419
24. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-1495
25. Klose S, Borner K. Enzymatische bestimmung des gesamtcholesterins mit dem Greiner Selective Analyzer (GSA II). J Clin Chem Clin Biochem 1978;15:121-130
26. Wahlefeld AW. Triglycerides - determination after enzymatic hydrolysis. In: Bergmeyer HV, editor, Methods of enzymatic analysis. 2nd edition. Verlag Chemie/Academic Press, New York, London; 1974. p. 18-31
27. Havel RJ, Edr HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345-1353
28. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502
29. Winer BJ. Statistical principles in experimental design. 2nd edition. McGraw-Hill, New York; 1971
30. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-2158
31. International Lipid Information Bureau. The ILIB lipid handbook for clinical practice: dyslipidemia and coronary heart disease. 3rd edition. New York; 2003. p. 1-242
32. Derosa G, Mugellini A, Ciccarelli L, et al. Effects of orlistat, simvastatin, and orlistat + simvastatin in obese patients with hypercholesterolemia: a randomized, open-label trial. Curr Ther Res Clin Exp 2002;63:621-633
33. Derosa G, Mugellini A, Ciccarelli L, Fogari R. Randomized double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both on anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. Clin Ther 2003;25:1107-1122
34. Derosa G, Cicero AFG, Murdolo G, et al. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. Diabetes Obes Metab 2005;7:47-55
35. Kelley FE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes. Diabetes Care 2002;25:1033-1041
36. Jacob S, Rabbia M, Meier MK, Hauptman J. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes Obes Metab 1999;4:361-371
37. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998;21:1288-1294
38. Dixon AN, Valsamakis G, Hanif MW, et al. Effect of the orlistat on serum endotoxin lipopolysaccharide and adipocytokines in South Asian individuals with impaired glucose tolerance. Int J Clin Pract 2008;62:1124-1129
39. Filippatos TD, Gazi IF, Liberopoulos EN, et al. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis 2007;193:428-437
40. Filippatos TD, Kiortsis DN, Liberopoulos EN, et al. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin 2005;21:1997-2006
41. Nakou ES, Filippatos TD, Georgoula M, et al. The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr Med Res Opin 2008;24:1919-1929
42. Mittendorfer B, Ostlund RF, Patterson BW, Klein S. Orlistat inhibits dietary cholesterol absorption. Obes Res 2001;9:599-604
43. Cho LW, Kilpatrick ES, Keevil BG, et al. Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. Clin Endocrinol 2009;70:233-237
44. Hsieh CJ, Wang PW, Liu RT, et al. Orlistat for obesity: benefits beyond weight loss. Diabetes Res Clin Pract 2005;67:78-83
45. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997;389:610-614
46. Hotamisligil GS. The role of TNF-alpha and TNF receptors in obesity and insulin resistance. J Intern Med 1999;245:621-625
47. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259:87-91
48. Jackson MB, Ahima RS. Neuroendocrine and metabolic effects of adipocyte-derived hormones. Clin Sci 2006;110:143-152
49. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002;13:84-89
50. Bouskila M, Pajvani UB, Scherer PE. Adiponectin: a relevant player in PPARgamma-agonist mediated improvements in hepatic insulin sensitivity? Int J Obes Relat Metab Disord 2005;29(Suppl 1):17-23
51. Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002;8:731-737
52. Berg AH, Combs TP, Du X, et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001;7:947-953
53. Kiortsis DN, Filippatos TD, Elisaf MF. The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabetes Metab 2005;31:15-22
54. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 2009;49:80-86
55. Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004;116:337-350
56. Zwacka TP, Hornbach V, Torzewski J. C-reactive protein-mediated lipoprotein uptake by macrophages. Circulation 2001;103:1194-1197
57. Yesilbursa D, Serdar A, Heper Y, et al. The effect of orlistat-induced weight loss on interleukin-6 and C-reactive protein levels in obese subjects. Acta Cardiol 2005;60:265-269
58. Valsamakis G, McTernan PG, Chetty R, et al. Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism 2004;53:430-434
59. Derosa G, Cicero AF, Murdolo G, et al. Comparison of metabolic effects of orlistat and sibutramine treatment in type 2 diabetic obese patients. Diabetes Nutr Metab 2004;17:222-229
60. Madsen EL, Rissanen A, Bruun JM, et al. Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study. Eur J Endocrinol 2008;158:179-187
61. Sundl I, Pail E, Mellitzer K, et al. Effects of orlistat therapy on plasma concentrations of oxygenated and hydrocarbon carotenoids. Lipids 2006;41:113-118